VK2735 Meets Phase 2 Obesity Endpoints as Viking Shares Tumble 37%

Introduction

Viking Therapeutics Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company based in San Diego, California. Founded in 2012, Viking focuses on developing therapies for metabolic and endocrine disorders, advancing candidates through various phases of clinical trials.

Corporate Structure

Viking Therapeutics has between 11 and 50 employees, facilitating a collaborative organizational structure that supports its research activities. The company's key programs include a non-steroidal selective androgen receptor modulator (SARM) currently in Phase 2 for post-hip fracture recovery, and a thyroid receptor beta (TRβ) agonist platform targeting lipid disorders as well as rare glycogen storage diseases.

Biopharmaceuticals by little plant

Recent Developments

• On August 19, 2025, Viking announced that its once-daily oral candidate VK2735 met both primary and secondary endpoints in a Phase 2 obesity study, achieving up to 12.2% mean body-weight reduction compared to placebo.
• A Form 8-K filed on the same day (SEC Acc-no: 0001607678-25-000003) provides further details about these efficacy results and related management commentary.
• On July 23, 2025, the company confirmed the initiation of Phase 3 VANQUISH registration trials for VK2735 and noted the completion of enrollment in the Phase 2 VENTURE oral-dosing study.
• June 25, 2025, filings provided designs for the VANQUISH-1 and VANQUISH-2 studies, focusing on subcutaneous VK2735 in obese adults with and without type 2 diabetes.
• On May 28, 2025, Viking reported milestones regarding its endocrine disorder pipeline, detailing advancements in both the SARM and TRβ programs.
• An amended Schedule 13G/A filed on August 6, 2025 (SEC Acc-no: 0000315066-25-002155) indicates that FMR LLC holds 8.7% of Viking’s outstanding shares.

Financial and Strategic Analysis

On August 19, 2025, VKTX closed at $26.49, reflecting a decrease of 37.06% on 5,140,472 shares traded, compared to an average volume of 3,856,659. Key metrics are summarized below:

Metric	Value
Share Price (Aug 19, 2025)	$26.49
Day Change	–37.06%
Volume	5,140,472
52-Week Range	$18.92 – $81.73
Market Capitalization	$4.7 billion
Cash and Cash Equivalents (mrq)	$807.7 million
Total Debt/Equity (mrq)	0.11%
Net Income Available to Common (TTM)	–$171.6 million
Diluted EPS (TTM)	–1.54
Profit Margin	0.00%

In its Second Quarter 2025 results (Form 10-Q filed July 23, 2025), Viking reported a net loss of $65.6 million, which was primarily driven by increased R&D expenditure. The company’s cash position of $808 million provides operational funding for ongoing and planned clinical activities.

Analyst coverage remains positive; analysts from Jefferies and Cantor Fitzgerald each reiterated Buy ratings in July 2025, with price targets set at $101 and $104, respectively. The consensus one-year target among analysts is at $89.28 (per Yahoo Finance).

Market Position and Industry Context

Viking operates in the competitive sector of metabolic and endocrine disorders within the biotechnology industry. As a clinical-stage company, its focus on trial outcomes and regulatory approvals differentiates it from commercial-stage peers. Located in the San Diego biotechnology hub, Viking has access to research institutions and potential collaborative partners. Notably, institutional ownership, including the 8.7% stake held by FMR LLC, reflects investor confidence in the company’s developmental pipeline.

tl;dr

On August 19, 2025, Viking announced that VK2735 met statistical endpoints in a Phase 2 obesity trial, while its share price declined by 37% to $26.49. The Phase 3 VANQUISH studies are currently ongoing, and Phase 2 VENTURE enrollment has been finalized. The company has $808 million in cash, bolstered in part by institutional investors including FMR LLC (8.7% ownership). Future developments include detailed data presentations from Phase 2 trials and interim analyses from Phase 3 trials, with the next earnings report scheduled for October 22, 2025.